Oculoplastics

Lower dose of teprotumumab may be effective in active TED with less adverse events

Sensorineural hearing loss has been associated with the use of teprotumumab in patients with thyroid eye disease (TED). A recent case report details the use of half-dose teprotumumab in a 64-year-old female with active moderate-severe TED. The patient experienced significant sensorineural hearing loss after 4 infusions of teprotumumab and discontinued...